Aethlon medical to present new pre-clinical data at the keystone symposium on long covid and other post-acute infection syndromes

Poster presentation reviews the hemopurifier ® affinity resin's a bility to bind extracellular vesicles in long covid samples san diego , june 9, 2025 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the keystone symposium on long covid and other post-acute infection syndromes being held at eldorado hotel & spa, santa fe, nm, united states, august 10-13,2025 (https://www.keystonesymposia.org/conferences/conference-listing/meeting/program-highlights/f12026). long covid refers to persistent symptoms following acute sars-cov-2 infection (covid-19).
AEMD Ratings Summary
AEMD Quant Ranking